Table 1.
Baseline patient characteristics—safety population (N = 23)
| Parameter | Cohort 3 (Bel D1-3) n = 8 |
Cohort 5 + Expansion (Bel D1-5) n = 15 |
Total N = 23 |
|
|---|---|---|---|---|
| Age (Years) | Mean ± SD | 61.9 ± 13.75 | 62.5 ± 8.91 | 62.3 ± 10.52 |
| Median (range) | 62.5 (35, 84) | 63.0 (44, 77) | 63.0 (35, 84) | |
| Gender, n (%) | Female | 4 (50) | 4 (27) | 8 (35) |
| Male | 4 (50) | 11 (73) | 15 (65) | |
| Race, n (%) | White | 6 (75 | 9 (60) | 15 (65) |
| Black or African American | 2 (25) | 4 (27) | 6 (26) | |
| Latino | 0 | 1 (7) | 1 (4) | |
| Other | 0 | 1 (7) | 1 (4) | |
| ECOG Performance Status, n (%) | 0 | 3 (38) | 6 (40) | 9 (39) |
| 1 | 5 (63) | 7 (47) | 12 (52) | |
| 2 | 0 | 2 (13) | 2 (9) | |
|
PTCL Subtype, n (%) |
ALCL, ALK-negative | 1 (13) | 0 | 1 (4) |
| ALCL, ALK-positive | 1 (13) | 1 (7) | 2 (9) | |
| Angioimmunoblastic TCL | 1 (13) | 9 (60) | 10 (43) | |
| Cytotoxic T-cell phenotype | 0 | 1 (7) | 1 (4) | |
| PTCL NOS | 5 (63) | 4 (27) | 9 (39) | |
| Disease Stage, n (%) | IIB | 0 | 2 (13) | 2 (9) |
| IIIA | 3 (38) | 2 (13) | 5 (22) | |
| IIIB | 0 | 2 (13) | 2 (9) | |
| IVA | 1 (13) | 5 (33) | 6 (26) | |
| IV B | 4 (50) | 4 (27) | 8 (35) | |
| International Prognostic Index | 0—Low Risk | 0 (0) | 1 (7) | 1 (4) |
| 1—Low-Intermediate Risk | 3 (38) | 3 (20) | 6 (26) | |
| 2—High-Intermediate Risk | 4 (50) | 7 (47) | 11 (48) | |
| 3—High Risk | 1 (13) | 4 (27) | 5 (22) |
ALCL anaplastic large cell lymphoma, ALK anaplastic lymphoma kinase, Bel belinostat, D day, ECOG Eastern Cooperative Oncology Group, n or N number, NOS not otherwise specified, PTCL peripheral T-cell lymphoma, SD standard deviation, TCL T-cell lymphoma